| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.14 | 0.007 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.099 | 0.03 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.092 | 0.04 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.086 | 0.06 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.078 | 0.07 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.061 | 0.2 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.058 | 0.2 |